<DOC>
	<DOCNO>NCT01381536</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics ( PK ) pharmacodynamics ( PD ) GSK1550188 Japanese subject Systemic Lupus Erythematosus ( SLE ) .</brief_summary>
	<brief_title>Phase I Study GSK1550188 Japanese Subjects With Systemic Lupus Erythematosus ( SLE )</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Subjects give consent study participation sign informed consent form . Subjects least 20 year age Screening visit . Have clinical diagnosis Systemic Lupus Erythematosus ( SLE ) accord American College Rheumatology ( ACR ) classification criterion , 4 11 ACR criterion present , serially simultaneously interval observation . Be either SLE medication stable SLE treatment regimen medication ( e.g. , lowdose prednisone , NSAIDs ; alone combination ) period least 2 month prior Screening visit . Males female . A female subject eligible enter study least one follow condition apply : Not pregnant nursing ; Of nonchildbearing potential ( ie , woman hysterectomy , postmenopausal define 1 year without menses , ovary surgically remove current document tubal ligation ) ; Of childbearing potential ( ie , woman functional ovary document impairment oviductal uterine function would cause sterility ) . This category include woman oligomenorrhoea [ even severe ] , woman perimenopausal begin menstruate . These woman must negative serum pregnancy test screening , agree 1 follow : Complete abstinence penilevaginal intercourse , female 's preferred usual lifestyle , 2 week prior administration 1st dose investigational product 8 week last dose investigational product ; Consistent correct use 1 follow acceptable method birth control 1 month prior start investigational product 8 week last dose investigational product : Implants etonogestrel levonorgestrel ; Estrogenic vaginal ring Injectable progesterone Any intrauterine device ( IUD ) intrauterine system ( IUS ) document failure rate le 1 % per year Oral contraceptive ( either combine progesterone ) Double barrier method vaginal spermicidal agent : Condom occlusive cap ( cervical cap/vault diaphragm ) vaginal spermicidal agent ( foam/gel/film/cream/suppository ) Percutaneous contraceptive patch The subject positive test antinuclear antibody ( ANA ) antidsDNA antibody serum Active lupus nephritis require hemodialysis , intravenous cyclophosphamide ( Cytoxan ) , highdose prednisone ( &gt; 60 mg/day ) within 6 month prior Screening visit The subject severe lupus kidney disease ( define proteinuria &gt; 6 g/day ) within 6 month prior Screening visit . Received IVIG plasmapheresis within 6 month prior Screening visit Active CNS lupus [ include seizure , psychosis , organic brain syndrome , cerebrovascular accident ( CVA ) , motor neuropathy , vasculitis ] require medical intervention within 6 month prior Screening visit The subject hypogammaglobulinemia IgA deficiency ( IgA level &lt; 10 mg/dL ) History renal transplant History clinical evidence active significant acute chronic disease ( i.e. , cardiovascular , pulmonary , untreated hypertension , anemia , gastrointestinal , hepatic , renal , neurological , cancer , infectious disease ) , opinion investigator , could confound result study put subject undue risk History medical disease , laboratory abnormality , condition would make subject ( opinion Investigator ) unsuitable study History infection require hospitalization parenteral antibiotic within 4 week prior Screening visit The subject abnormality 12lead ECG screen clinically significant opinion investigator . The subject currently participate another clinical study postmarketing study subject expose investigational agent . The subject receive biologic investigational noninvestigational agent within 12 month prior dose day . The subject receive nonbiologic investigational agent within 2 month prior dose day . Have evidence current drug alcohol abuse dependence . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) 2x upper limit normal ( ULN ) ; alkaline phosphatase bilirubin &gt; 1.5xULN ( isolated bilirubin &gt; 1.5ULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Have historically positive HIV test test positive screening HIV . History , positive test Screening visit HBsAg , antiHBcAb antiHCVAb . If antiHBcAb result positive , HBVDNA test performed . If HBVDNA result negative , patient eligible .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Anti Blys Antibody</keyword>
</DOC>